ArcticZymes Technologies Q1 2021 Results
Tromsø, Norway, 22 April 2021 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 40.4 million (18.5) and an EBITDA of NOK 25.8 million (9.0) for the first quarter of 2021.
Highlights from Q1 2021
- ArcticZymes Technologies (AZT) had Q1 sales of NOK 40.4 million growing by 119% (Q1 2020: NOK 18.5 million)
- Coronavirus-related sales are estimated at NOK 16.5 million in Q1 2021 (NOK 3.8 million in Q1 2020)
- Gross profit improved to NOK 39.9 million with 99% margin (Q1 2020: NOK 18.5 Million)
- AZT delivered a positive EBITDA of NOK 25.8 million (Q1 2020: NOK 9.0 million)
- Cash-flow for Q1 was positive NOK 23.2 million (Q1 2020: NOK 4.4 million) giving a cash balance of NOK 163.3 million (Q1 2020: NOK 35.7 million)
- Successfully upscaled the SAN HQ production process
CEO Jethro Holter comments:
“We are delighted with the performance of our first quarter as a pure enzymes company. The ArcticZymes team has delivered the best ever quarterly performance achieving sales revenues of 40 million NOK and an EBITDA of 26 million NOK. All market segments have experienced quarterly growth including re-establishment of molecular research sales to pre-pandemic levels.
Furthermore, the SAN HQ enzyme production process was successfully upscaled 100-fold. The innovation pipeline and the infrastructure expansion project of R&D and operations are progressing. Such activities are key to leveraging the greater potential ArcticZymes Technologies can accomplish through organic growth.”
First Quarter 2021 Presentation and Webcast
A presentation by ArcticZymes Technologies’ CEO, Jethro Holter and CFO, Børge Sørvoll will take place today, 22nd April 2021, at 08:30 am CET as a live video/phone -conference.
Call in details: +47 21 40 24 87 with conference id: 246 245 401#. Participants who want to participate in the Teams webcast are asked to send an email to email@example.com for a separate invitation.
The results, report and presentation for the first quarter 2021 will be available on www.newsweb.no and on the Company's homepage www.arcticzymes.com from 07:00 am on 22th April 2021.
For more information, please contact:
|ArcticZymes Technologies ASA|
|CEO, Jethro Holter
CFO, Børge Sørvoll
|Tel: +47 46 85 91 46
Tel: +47 95 29 01 87
About ArcticZymes Technologies ASA
ArcticZymes Technologies is a Norwegian life sciences company focused on the development, manufacturing and commercialization of novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and therapeutics.
Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec] ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre.
ArcticZymes Technologies’ IP and capabilities are protected via a large portfolio of patents.
For more information, please visit the website: www.arcticzymes.com.